WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics

WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics

Client News
On November 25, 2019, Alkermes plc announced the completion of its previously announced acquisition of Rodin Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. The WilmerHale team representing Alkermes was led by Stuart Falber, Joe Conahan and Mark Nylen and included Julie Hogan Rodgers, Scott Kilgore, Steve Barrett, Bruce Manheim, Barry Hurewitz, Hartmut Schneider, Paul Jakubowski, Ben Unger, Ben Kelsey, Lauren Ige, Meghan Fay and Meghan Muncey.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.